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Abstract
This study examined the impact of Type 1 Diabetes Mellitus (T1DM) on executive
function using a series of operant conditioning based tasks in rats. Sprague Dawley rats were
randomized to either non-diabetic (n = 12; 6 male) or diabetic (n = 14; 6 male) groups. Diabetes
was induced using multiple low-dose streptozotocin injections. All diabetic rodents were
insulin-treated using subcutaneous insulin pellet implants. At week 14 of the study, rats were
placed on a food restricted diet to induce 5 - 10% weight loss. Rodents were familiarized and
tested on a series of tasks that required continuous adjustments to novel stimulus-reward
paradigms in order to receive food rewards. No differences were observed in the number of
trials, nor number / type of errors made to successfully complete each task between groups.
Therefore, we report no differences in executive function, or more specifically set-shifting
abilities between non-diabetic and diabetic rodents.

Keywords
Type 1 diabetes mellitus, cognition, executive function, set-shifting, reversal learning, brain,
rat, insulin
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Summary for Lay Audience
Type 1 Diabetes Mellitus (T1DM) is a disease in which the body loses the ability to
produce insulin, a hormone that helps regulate blood sugar and provides energy to bodily
tissues. Although there is no cure, patients with T1DM can lead a relatively normal life thanks
to the invention of pharmaceutical insulin. However, T1DM increases risk of both short(seizure, diabetic coma) and long-term (heart disease, vision and nerve problems) health
complications. There have also been several studies that have demonstrated that patients with
T1DM have minor brain abnormalities that may impair cognition. Research in both humans
and animals has shown that T1DM is associated with decreased performance in tests of
intelligence, information processing, and cognitive flexibility. Cognitive flexibility (also
referred to as set-shifting) measures one’s ability to adapt to changing circumstances or
“outside of the box thinking”. Many prior studies in animals have examined cognition,
however very few have used tests that specifically assessed cognitive flexibility. Furthermore,
very few animal studies have used rodents that were insulin-treated, the standard treatment for
patients with T1DM. Therefore, the purpose of this study was to test the set-shifting abilities
of insulin-treated T1DM rats compared to non-diabetic rats. Rats were randomly divided into
two groups: twelve non-diabetic (six male, six female) and fourteen diabetic (six male, eight
female). At week 14 of the study, rats were put on a food restricted diet to help motivate them
to complete the set-shifting tasks. Once they lost 5% of their body weight, rats were
familiarized with the testing apparatus and then progressed through three unique tasks. Each
task corresponded to a specific rule that the rat must learn in order to receive a food reward.
The number of trials it took for the rat to fully learn the rule, as well as the number of errors
they accrued in learning the rule were recorded. There were no differences in either measure
across the three tasks that were completed. Therefore, we conclude that insulin-treated T1DM
rats do not show any decreases in cognitive ability, or more specifically set-shifting, compared
to non-diabetic rats.
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Chapter 1

2

1

Literature Review

1.1 Overview of Type 1 Diabetes Mellitus
Diabetes mellitus (DM) refers to a category of disorders with the commonality of
insulin dysfunction, and resultant chronic hyperglycemia (high blood glucose). Although
they may be classified similarly, the two main types of diabetes (type 1 and type 2) are
independent diseases with unique etiologies and complications.
Glucose metabolism involves contributions from many different organ systems and
pathways including the liver, pancreas, and skeletal muscle 1. Fundamentally, blood
glucose is controlled by two antagonistic hormones. Glucagon acts to release stored
glucose into the bloodstream, ultimately raising blood glucose. Conversely, insulin acts to
facilitate glucose uptake into target tissues, such as skeletal muscle, lowering blood glucose
in the process 2.
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized
by the destruction of the insulin producing β-cells of the pancreas 3. This results in a partial,
or more often complete inability for the body to produce insulin, leading to unregulated
hyperglycemia 4. As such, patients with T1DM are dependent on exogenous insulin
typically administered via injection, or insulin pump. Patients with T1DM must continually
monitor and delicately modulate both insulin and blood glucose levels in order to maintain
euglycemia (normal blood sugar). If left unregulated, acute hypoglycemia (low blood
glucose) can have catastrophic consequences such as seizures, coma, or in rare instances
death 5. T1DM may also result in long-term complications such as cardiovascular disease,
neuropathies, and retinopathies, among others

6-8.

The cause(s) of T1DM remain largely

unknown, however genetic, immunologic, and environmental contributions are likely
factors 9.
In contrast, type 2 diabetes mellitus (T2DM) is a metabolic disease occurring as a
result of a combination of genetic and environmental risk factors, some of which are
controllable (diet, sedentary behaviour, and/or obesity)

10.

T2DM is characterized by

progressive insulin resistance (IR) coupled with chronically elevated insulin levels
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(hyperinsulinemia), and hyperglycemia 11. As target tissues become resistant to the effects
of insulin, the pancreas compensates by secreting more insulin, leading to a
hyperinsulinemic environment. IR directly affects the body’s ability to clear glucose from
the bloodstream, and over time will result in a state of chronic hyperglycemia, the hallmark
symptom of T2DM. Although several treatment options are available, patients with T2DM
can eventually become insulin dependent.
Historically, T1DM was referred to as juvenile diabetes as it was thought to occur
only in children. It has since been reclassified as type 1 diabetes mellitus, as onset may
occur at any age, although it is most common in children under 14 years old

12.

T1DM

onset is usually accompanied by polydipsia, polyphagia, and polyuria (excessive thirst,
hunger, and urination, respectively) 13. Diagnosis is typically confirmed when any of the
three following criteria are met: fasting blood glucose > 7 mmol/L, any blood glucose value
> 11.1 mmol/L, or an HbA1c value of 6.5% or higher 14, 15. HbA1c is a form of hemoglobin,
an oxygen transporting protein found in red blood cells, that has been bound to glucose in
a process called glycation. This is a normally occurring process, however sustained
hyperglycemia will lead to a higher concentration of HbA1c. Hemoglobin that has been
glycated will remain so for the lifespan of the red blood cell, which is approximately 120
days

16.

As a result, HbA1c concentration serves as an indicator of long-term glycemic

control and is a hallmark indicator of both T1DM and T2DM management

17.

In an

otherwise healthy individual, HbA1c is below 5.7%. A higher HbA1c value indicates poor
glycemic control and even as little as a 1% increase has been shown to correspond to a
30% increase in all-cause mortality 18.
Although tremendous progress has been made in regard to the knowledge and
treatment of T1DM, there is presently no cure, nor means of predicting or preventing
disease onset. Moreover, the incidence rate of T1DM has increased globally by
approximately 3% over the past 30 years and is predicted to continue to trend upwards
20.

19,

It is reported that there are approximately 300,000 Canadians currently living with

T1DM, and this number is expected to grow to nearly 400,000 by the year 2030 21.
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In a landmark study that permanently altered the landscape of T1DM patient care,
The Diabetes Control and Complications Trial (DCCT) sought to explore the outcome of
stricter glycemic control on long-term complications of T1DM 22. Patients were randomly
allocated to receive either conventional insulin therapy consisting of one or two insulin
injections per day, or intensive insulin therapy, which included the administration of insulin
three or more times per day with the goal of maintaining strict blood glucose values within
the range of 4 - 7 mmol/L. At the end of the study, it was apparent that intensive insulin
treatment significantly reduced several diabetic comorbidities. More specifically, intensive
insulin treatment was shown to reduce HbA1c by approximately 2%, as well as reduce the
risk of developing retinopathy, nephropathy, and neuropathy, amongst other positive
benefits. Intensive insulin therapy has since been adopted into clinical care as a direct result
of these findings and has vastly improved the long-term health and wellbeing of those with
T1DM.

1.2 Type 1 Diabetes Mellitus and Cognition
Glucose, a simple sugar, is an essential source of energy in humans, playing a
critical role in the metabolic processes of nearly every tissue. Perhaps most importantly,
the human brain is an obligate glucose user, consuming up to 60% of circulating blood
glucose in a fasted, sedentary state 1. The human brain functions as the core of the central
nervous system, controlling nearly every aspect of our body including cognition, sensory
processing, and motor control. Due to its critical function, complex control systems
regulate blood glucose homeostasis, ensuring it remains within a physiological range of 4
- 6 mmol/L (in a fasted state). Since the consequences of extreme and/or sustained
deviations outside of this range can be catastrophic 5, the preservation of a euglycemic state
is crucial to survival. Given the sensitivity of the brain and the perturbations in glycemic
control caused by metabolic disorders such as T1DM, it is not surprising that there are links
between metabolic disorders and brain dysfunction. Indeed, T1DM has been shown to
result in varying degrees of impairment across different cognitive domains

23.

Cognitive

impairments specifically refer to deficits in neurophysiological processes such as memory,
learning, concentration, and/or decision making 24.
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As early as 1922, diabetes mellitus has been implicated as a contributor to cognitive
impairments. Miles et al. 25 demonstrated that patients with diabetes displayed a decrement
of approximately 15% in tests of memory and attention compared to healthy individuals.
Interestingly, they also noted that with treatment, patients with diabetes rapidly recovered
their performance to “near normal” levels. Since this seminal work, many studies have
specifically examined the relationship between T1DM and cognition presenting similar
findings.
Brands et al. 23 conducted a meta-analysis including thirty-three studies comparing
the cognitive performance of T1DM adults (minimum 18 years post-diagnosis) to their
non-diabetic counterparts. T1DM groups demonstrated significantly lower performance in
an array of cognitive domains including: intelligence, information processing,
psychomotor efficiency, visual and sustained attention, cognitive flexibility (also referred
to as “set-shifting”), and visual perception. However, learning and memory domains were
spared. Impaired cognition appeared to be correlated with microvascular complication, but
not severe hypoglycemic events, nor poor metabolic control.
Executive function (EF) is an integral component of cognition and is especially
pertinent in relation to T1DM management as it requires intricate care 26. EF encapsulates
specific mental processes including inhibition, interference control, working memory, and
cognitive flexibility 27 that underlie human behaviour and learning. EF is governed mainly
by the frontal lobe of the brain (which includes the prefrontal cortex), with the parietal and
cerebellar lobes also serving important roles

28.

Impairments in EF are of particular

importance to the patient with T1DM since deficits in these skills are associated with
inferior self-regulation, planning, problem-solving and decision making

29.

These

behaviours are all important in diabetes management and may be a key factor contributing
to clinical outcomes of T1DM. A recent analysis has shown subtle, but significant
impairments in groups with T1DM across inhibition, working memory, and set-shifting
domains

30.

Several risk factors such as age at onset, prior hypoglycemic episodes, and

chronic hyperglycemia were explored in this analysis. Although some significant results
were reported, the authors note that there may not be enough data to draw definitive
conclusions regarding the effect of specific risk factors on EF. Given this, and the paucity
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of data specifically assessing EF / set-shifting in T1DM populations, data pertaining to
T1DM and more general measures of cognition will be explored throughout this chapter.
Cognitive dysfunction has also been observed in younger populations. Metaanalysis data in children aged nineteen or younger demonstrated lower performance across
multiple cognitive domains amongst those with T1DM compared to non-diabetics

31.

Similar to results from Brands et al. 23, learning and memory were unaffected by T1DM.
Subgroup analysis of this study determined that children with early-onset diabetes (< 7
years old at diagnosis) performed worse than those with late-onset diabetes. This finding
is supported by a subsequent large-scale population-based study in Sweden which found
that children with T1DM scored lower grades in school and were more likely to fail their
classes 32. These negative effects appeared to be magnified amongst those with a younger
age at diabetes onset, suggesting that the age at onset of diabetes may be a determinant of
cognitive function.
Since there is an established consensus across the literature recognizing cognitive
impairments as a comorbidity of T1DM, we will next investigate potential risk factors of
impaired cognition. Due to the vast amount of literature and the complexity of certain
underlying mechanisms, only a handful of landmark studies will be discussed. This is
appropriate given the scope of this project and its lack of biochemical and histological
analysis. As evidenced above, it appears that age at diabetes onset may be an important
risk factor in relation to the development of cognitive dysfunction

31, 32.

This is theorized

to be due to chronic hyperglycemia induced structural and functional changes that
adversely affect the central nervous system at crucial periods of development in children
33.

More specifically, the medial prefrontal regions, insula, and cerebellum were shown to

be negatively altered in children with early onset T1DM 34.
Metadata from Brands et al.

23

presented above implicated microvascular

complications as a determinant of cognitive dysfunction. This is supported by both cross
sectional 35, 36 and longitudinal 37, 38 data which demonstrates that cognitive dysfunction is
associated with retinopathies, nephropathies, neuropathies and other microvascular
pathologies in adults with T1DM. The reasons for this are complex and not entirely clear,
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however in a recent review, impaired vascular tone, capillary plugging, and blood brain
barrier disruption were purported as potential mechanisms 39.
An epidemiological follow-up study to the aforementioned DCCT, titled
Epidemiology of Diabetes Interventions and Complications (EDIC), followed 1144 patents
for 18 years. Neither prior severe hypoglycemic events, nor intensive versus conventional
insulin therapy had any effect on the assessed cognitive domains. However, both higher
HbA1c levels and the presence of microvascular complications were associated with
impaired performance in certain cognitive domains 38. Participants with poorer metabolic
control (HbA1c > 8.8%) performed significantly worse on measures of psychomotor
efficiency and speed compared to those with better control (HbA1c < 7.4%). It is thought
that poor long-term metabolic control perhaps serves as a proxy to the development of
diabetic comorbidities such as microvascular complications, which in turn explains the
observed cognitive dysfunction 37. This may in part explain why metadata from Brands et
al. 23 implicated microvascular complications but found no independent effect of metabolic
control on cognition.
Although the evidence seems to clearly outline a relationship between, long-term
glycemic control and cognition, the effect of prior severe hypoglycemic episodes on
subsequent cognition remains ambiguous. As outlined above, severe hypoglycemia is a
complication of insulin therapy which can have profoundly negative effects on the body 5.
It is well documented that cognition may be impaired during transient states of severe
hypoglycemia

40, 41,

however it is not clear how these acute states affect future cognitive

performance in the long-term. The EDIC 38 showed that the cumulative number of severe
hypoglycemic events did not affect performance in any cognitive domain. This finding is
replicated by high quality data from several other works 23, 36 , 42 ,43. However, some crosssectional studies

44-46,

as well as a recent, large scale perspective cohort study

47

demonstrated evidence that prior severe hypoglycemic episodes do not affect cognition.
Given the constraints and potential ramifications of manipulating long-term
glycemic control in humans, the majority of research presented thus far is observational in
nature. Experimental work in pre-clinical animal models can provide important insight into
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certain factors that are not feasible to manipulate in humans. Several studies in rats and
mice have also shown that cognitive decrements exist in a T1DM population relative to
respective non-T1DM counterparts 48-51. An important consideration is the effect of insulin,
since it is not always utilized as a treatment strategy in diabetic animal models. In a
landmark paper, Biessels et al.

52

demonstrated that insulin treatment was effective at

preventing cognitive decrements in streptozotocin (STZ)-induced T1DM rats.
Interestingly, insulin was effective at preserving cognitive performance if immediately
administered following diabetes induction, however if insulin treatment was deferred to
later in the course of the disease (administered ten weeks following diabetes induction),
cognitive deficits were observed. A more recent study found similar results

53,

showing

that insulin treatment administered immediately following diabetes induction preserved the
performance of rats in cognitive assessments when compared to non-insulin treated
diabetic rats. However, insulin treatment only partially prevented adverse structural and
hormonal changes.
Although there is mixed evidence over which specific domains are affected and the
impact of specific risk factors, it is clear that the literature provides strong evidence for a
relationship between T1DM and cognitive impairment. Age at diabetes onset, long-term
glycemic control, microvascular complications, as well as the administration of insulin all
appear to modulate the presence and severity of both cognitive dysfunction and structural
alterations.

1.3 Methods of Assessing Cognitive Function
There are many valid methods of assessing cognitive function in a wide variety of
animal models and in humans, each requiring the use of various cognitive domains and
corresponding brain areas. Given the abundance of assessment methods available
throughout the literature, only a few relevant cognitive assessment tools will be discussed.
The majority of research carried out in T1DM rodent models to date has utilized tests that
assess predominantly hippocampal function such as the Morris Water Maze (MWM), or
the Object Recognition Task (ORT). The ORT is sometimes referred to as “Novel ORT”
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or “Object-placement Recognition Task”, but will be addressed simply as ORT in this
review. The hippocampus is comma-shaped component of the brain found deep within the
medial temporal lobe 54. It serves important roles in learning and memory consolidation,
especially in spatial tasks 55.
The MWM, pioneered by Dr. Richard Morris in 1981

56, 57,

is a hippocampal-

dependent assessment of spatial learning and memory. This is evidenced by data showing
attenuated MWM performance among rats with induced hippocampal lesions

58.

In the

MWM, rodents are placed in a large circular pool of opaque water and must search for a
hidden platform that allows them to escape and be rescued by research personnel. Escape
latency and total distance travelled are typically measured, with lower values indicating
better performance 57. Several experimental studies in a variety of T1DM rodent models
have assessed cognition using this task, showing decrements in performance, and when
measured, hippocampal abnormalities in comparison to non-diabetic groups

48-50, 59-63.

Notably however, none of these studies attempted to regulate glycemia with the use of
insulin or other compounds. As a result, many studies were conducted in rodent populations
with extreme levels of hyperglycemia (> 20 mmol/L). Work from Biessels et al. 52 outlined
above demonstrated that insulin-treated rodents did not show any differences in MWM
performance compared to non-diabetic controls. Subsequent work from Biessels et al.

64

followed a similar theme, demonstrating that only severely hyperglycemic rats (25.6 ± 1.0
mmol/L) showed decrements in MWM performance, but not moderately hyperglycemic
rats (18.9 ± 1.8 mmol/L). The MWM is a valid, well-established cognitive assessment that
can be applied to a variety of rodent populations. However, performance is heavily dictated
by hippocampal function, and spatial learning and memory are among the only cognitive
domains assessed 65.
Another common cognitive assessment used in rodent models is the ORT, first
developed by Ennaceur & Delacour

66

in 1988. The ORT involves visual exploration of

two or more objects, relying on rodents’ unconditioned preference for exploring novel
objects

67.

The greater amount of time that a rodent spends exploring the novel object

signifies that they recognize it as novel, serving as a positive measure of learning and
memory. Although there are subtle differences compared to the MWM, the ORT primarily
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assesses learning and memory, which is mainly governed by the hippocampus 68, 69. More
specifically, the ORT does not rely as heavily on spatial learning, is modifiable to evaluate
different types of memory (spatial, working, short-, or long-term), and is less stressful than
other cognitive tests 70. The ORT has been used in several induced T1DM-rodent model
studies, consistently demonstrating that non-T1DM animals outperform T1DM animals 49,
51, 53, 71.

In accordance with earlier aforementioned studies

52, 53,

Kassab et al.

71

demonstrated that insulin treatment ameliorated deficits amongst T1DM rodents in the
ORT. Overall, the ORT is a flexible and simple assessment of cognitive function in animal
models. However, it is limited in the amount of information it can yield and may not serve
as a complete measure of overall cognitive function 70.
As outlined above, EF refers to higher-level cognitive skills that enable us to
regulate behaviour within the context of goal setting or rules, and includes specific setshifting skills 72. Developed by Grant et al.

73

in 1948, the Wisconsin Card Sorting Task

(WCST) is perhaps the most classic assessment of EF / set-shifting ability in humans. In
this task, unacquainted subjects must learn to sort cards based on one of three distinct
dimensions (number, colour, or shape). The paradigm will eventually shift unannounced,
and subjects must adapt their sorting to align with one of the other two previously irrelevant
dimensions. This test is mainly governed by frontal lobe function 74, although other, more
specific areas have been implicated more recently

75, 76.

The WCST generates a rich data

set that includes insight into the number and type of errors committed.
Most of the literature in rodent models outlined thus far has utilized cognitive
assessments that rely primarily on spatial learning and memory-based tasks (MWM, ORT).
Although less commonly used, there are a handful of tasks that assess EF / set-shifting
developed for use in rodents 77. Set-shifting ability can be measured using tasks conducted
in radial-arm or cross-mazes that assess rodents’ ability to transition from one stimulusresponse strategy to another, inhibiting the former strategy in the process
Brown

82

78-81.

Birrell &

developed a more intricate procedure resembling the WCST where rodents are

trained to dig for a food reward based on three separate dimensions: odour, digging
medium, or texture. Rodents are assessed on their ability to complete both intradimensional
and extradimensional shifts, as well as reversal learning (RL) tasks. Disruptions to the
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medial prefrontal cortex (mPFC) have been shown to impair set-shifting performance, but
not reversal learning, indicating that the mPFC may specifically underlie set-shifting ability
83.

In the same study, inhibitions of the orbitofrontal region of the PFC resulted in

decrements in reversal learning, but not set-shifting ability, providing evidence that distinct
regions of the PFC regulate different domains of EF.
The aforementioned tests of set-shifting provide a highly valid assessment of EF
and mPFC function in rodents. However, they can require complicated set-up and are
limited by the overall throughput, as each animal must typically be individually monitored.
In 2008, Floresco et al. 84 established an automated set-shifting procedure utilizing similar
paradigms to the maze- and digging-based tests described above. In this procedure, rodents
are placed in an operant conditioning chamber fitted with two retractable levers and
progress through a series of learned contingencies, intradimensional and extradimensional
shifts. Taken as a whole, this assessment produces many meaningful metrics that serve as
detailed indicators of the different components of EF. Similar to other tests of behavioural
flexibility 83, Floresco and colleagues

84

demonstrated using this task that inactivation of

the mPFC impaired set-shifting, but not reversal learning performance.
To our knowledge, no prior work has examined the effects of T1DM on executive
function / set-shifting abilities using rodent models. In what is perhaps the only other body
of work to examine this area of research, the set-shifting abilities of rats subjected to
recurrent hypoglycemia were assessed using a maze-based test 85. They found that multiple
episodes of insulin-induced antecedent hypoglycemia led to impaired set-shifting
performance, accompanied by reduced PFC function. Although recurrent hypoglycemia is
a symptom of T1DM that may have potentially deleterious consequences, the rodents in
this experiment were never subjected to sustained hyperglycemia, a cornerstone symptom
of T1DM that appears to be implicated more often in cognitive dysfunction 38. Work from
Kaleeswari el al. 86 explored the impact of early stage T1DM on bar pressing in an operant
chamber task and found no differences in performance between control and T1DM rats.
Although this closely resembles the testing procedures used in the present study, there was
no visual cueing nor shifting of stimuli, making this task far less intricate. Also of
relevance, recent work demonstrated that the offspring of pregnant rats induced with
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gestational diabetes show attenuated set-shifting performance using the operant chamber
based procedure pioneered by Floresco et al. 84. Multiple works from Sharma et al.

87-89

have examined the effects of vascular dementia induced by experimental diabetes on
behavioural flexibility using an attentional set-shifting digging based task, consistently
showing deficits amongst the experimental groups compared to the controls.
There are several highly valid methods of assessing cognition in both humans and
animal models. The majority of research conducted on T1DM rodent models has utilized
hippocampal-dependent assessments such as the MWM or iterations of the ORT. It would
appear there is a consensus across the literature in that T1DM rodent models consistently
demonstrate inferior performance on these tasks when compared to non-T1DM
counterparts. Although tests of EF have existed for many years, very few animal studies
have specifically examined the impact of T1DM on EF or more specifically set-shifting.

1.4 Rationale
Over 300,000 Canadians and millions more globally are currently living with
T1DM 21. Although great strides have been made in improving disease related outcomes,
persons with diabetes remain at elevated risk for several comorbidities
cognitive dysfunction

23, 90.

18

including

EF is a vital component of cognition, as it includes mental

processes that allow for complex problem solving, self-regulation, and higher level
thinking 27. EF is of particular importance amongst T1DM populations, as impairments in
this area have been linked to poorer glycemic control

90.

In turn, poor glycemic control

(indicated by higher HbA1c) is well established as a causative factor leading to increased
risk of comorbidity development and all-cause mortality 18.
Several studies have examined the relationship between T1DM and cognitive
function in both humans 23 and animal models 91. More specifically, studies in humans have
examined EF in patients with T1DM

30,

however to our knowledge, no studies have

examined this relationship using pre-clinical animal models. Assessing EF using a rodent
model of T1DM may allow us to validate an experimental model to measure EF and

13

ascertain any potential underlying mechanisms of impaired EF. Although valid
assessments of EF have been adapted for use in rodents 66, 82, 84, they have not been utilized
in T1DM rodents. Furthermore, many of the studies that have examined cognition in rodent
models have not featured an insulin-treated group

48, 49, 51, 59, 60, 92, 93.

In many of these

studies, rodents are maintained at levels of extreme hyperglycemia (> 20 mmol/L) that may
potentially drive or further exacerbate cognitive dysfunction. Hence, this study serves to
address two main gaps in the literature: a) the lack of assessment of EF conducted in T1DM
rodent models, and b) the lack of general cognitive assessment in insulin-treated rodent
models.

1.5 Purpose and Hypothesis
Given the lack of prior work examining the executive function of T1DM rodents,
the purpose of the study was to evaluate the effect of T1DM on EF through the use of a
series of automated operant conditioning based tasks developed by Floresco et al.

84.

Specifically, we examined the ability of rodents in three tasks: visual cue discrimination,
response discrimination (set-shift), and reversal learning. Based on the literature
demonstrating reductions in measures of EF in humans 23, 30, and studies in rodents showing
attenuated MWM and/or ORT performance

48-53

we hypothesized that T1DM rodents

would show impairments in measures of EF. Given that the response discrimination task
best assesses set-shifting, a core pillar of EF, we specifically hypothesized that T1DM
rodents would show increases in both the number of trials, and the number of errors to
criterion (i.e. inferior performance).
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2

Assessment of Executive Function in T1DM Rodents

2.1 Introduction
Type 1 Diabetes Mellitus is a chronic condition which occurs as a result of an
autoimmune mediated destruction of the insulin producing β-cells of the pancreas 1. As a
result, patients with T1DM are unable to produce insulin and are typically reliant on
exogenous pharmaceutical insulin for survival. Insulin is a peptide hormone that is
responsible for facilitating the uptake of glucose from the bloodstream into target tissues
such as skeletal muscle. Without insulin, blood glucose levels remain chronically elevated,
and tissues are unable to receive glucose that they require for metabolism. Conversely,
patients with T1DM are also at risk of hypoglycemia that may be caused by overcorrections
in insulin treatment, sustained periods of fasting, or prolonged exercise. If untreated,
extreme hypoglycemia can cause severe symptoms such as seizures, coma, or in rare
instances death 2. Prior to the invention of insulin in 1921 by Frederick Banting and Charles
Best, it was uncommon for those diagnosed with diabetes to live for more than a few years.
Despite the great advances that have been made in regard to the understanding and
treatment of T1DM, there is still no cure presently available. Although patients with T1DM
can effectively live a normal life, they face an elevated risk of comorbidities such as
cardiovascular disease, neuropathies, and retinopathies 3-5.
The human brain is an obligate glucose consumer and functions as the core of the
central nervous system, governing bodily processes including cognition, sensory
processing, and motor control. Despite comprising only ~ 2% of body weight, the brain
consumes up to 60% of circulating blood glucose in a fasted, sedentary state 6. Due to the
critical function of the brain and its reliance on glucose, intricate mechanisms tightly
regulate blood glucose. Given the perturbations in glycemic control caused metabolic
diseases such as diabetes, it is not surprising that brain dysfunction may arise. A link
between cognitive dysfunction and patients with T1DM was first identified as early as 1922
when Miles et al. 7 found that patients with diabetes scored approximately 15% lower on
tests of memory and attention compared to non-diabetic counterparts. Many subsequent
works

8-11

have reported similar findings and provide much greater insight into the risk

factors and mechanisms that may lead to cognitive dysfunction in patients with T1DM.
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A 2005 meta-analysis of thirty-three studies comparing cognitive performance of
T1DM to non-T1DM adults reported that patients with T1DM demonstrated minor, but
significant decrements in specific cognitive domains including: intelligence, information
processing, psychomotor efficiency, visual and sustained attention, cognitive flexibility,
and visual perception 8. Similar findings have also been reported in younger populations 12,
13.

There are several risk factors and underlying mechanisms that have been identified that

may contribute to cognitive dysfunction in T1DM populations. Several high-quality works
have implicated microvascular complications as a contributing factor in cognitive
dysfunction 9, 14-16. Although a causal relationship was not definitively established in these
works, a recent review has proposed several mechanisms that may be responsible 17. Earlier
age at diabetes onset, as well as poor long-term metabolic control have also been correlated
with greater decrements in cognition in patients with T1DM 9, 12, 13, 16.
Several experimental works in non-human subjects have also examined the
relationship between cognitive dysfunction and T1DM. In a seminal study, Biessels et al.
18

found that insulin therapy was able to preserve cognitive function in T1DM rats, but only

if it was initiated immediately following diabetes onset. A more recent study reached a
similar conclusion, demonstrating that insulin treatment was able to rescue cognitive
impairments, however it was not able to fully prevent structural nor hormonal changes 19.
Executive function is a domain of cognition that encapsulates specific mental
processes such as inhibition, working memory, and cognitive flexibility 20. EF is controlled
primarily by the frontal, parietal, and cerebellar areas of the brain 21. Similar to results on
general cognition presented above, patients with T1DM score lower on specific
assessments of EF

22.

Several experimental works in rodents have demonstrated that

cognition is generally attenuated amongst T1DM groups using tests such as the Morris
Water Maze 23-30 or the Object Recognition Task 19, 24, 31, 32. However, both of these tests
are measures of spatial learning and memory that are primarily hippocampal-dependent 33,
34.

Although less commonly implemented, specific tests exist that assess EF in rodents 35.

EF, or more specifically behavioural flexibility can be assessed in rodents using mazeor a digging based task

38

using similar concepts to the Wisconsin Card

Sorting Task 39. In 2008, Floresco et al.

40

developed an automated set-shifting task that

based tasks

36, 37
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solves some of the shortcomings of the aforementioned tests. This task utilizes an operant
conditioning chamber fitted with two levers where rodents must continually adjust to
shifting paradigms in order to receive food rewards.
Although a handful of studies in humans have specifically examined executive
function and set-shifting abilities of patients with T1DM 22, to our knowledge, no studies
have specifically examined this relationship in animal models. By assessing EF in a rodent
model of T1DM, we aim to validate an experimental model to measure EF, and ascertain
any potential underlying mechanisms of impaired EF. Hence, the purpose of this study was
to compare the EF of non-diabetic rats to insulin-treated diabetic rats using a series of
operant conditioning based tasks outlined above

40-42.

Both male and female rats were

randomly assigned to either a non-diabetic group (n = 12), or an insulin-treated diabetic
group (n = 14). Rats underwent a series of tasks that assessed learning, inhibitory control,
behavioural flexibility, and reversal learning. We hypothesized that diabetic rats would
show performance decrements on these assessments of executive function. Specifically,
diabetic rats would require more trials to criterion, and incur more errors in reaching
criterion on the response discrimination (set-shifting) task.

2.2 Materials and Methods
2.2.1

Ethics Approval
All protocols utilized in this study were approved without stipulation by The

University Council of Animal Care of Western University (London, Ontario, Canada) and
conducted in accordance with the standards outlined by The Canadian Council on Animal
Care (CCAC).
2.2.2

Animals
Twenty-eight Sprague Dawley rats (fourteen male, fourteen female) were procured

from Charles River Laboratories (St. Constant, Quebec, Canada) at eight weeks of age.
One male rodent died from complications relating to diabetes induction (week 8), and a
second male died from complications relating to food restriction (week 14), leaving a final
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cohort of twelve males and fourteen females. Upon arrival at the animal holding facility,
all rats were acclimatized for a minimum of 72 hours before handling. Rats were housed
together in same sex pairs until food restriction, at which point all animals were housed
individually for the duration of the study. All rats were maintained on a 12:12 hr alternating
light/dark cycle (lights on at 07:00 AM). Room temperature was held at a constant 21 ±
2°C and relative humidity was maintained at 40 - 50% throughout the duration of rodents’
lifespan. All rats were provided ad libitum access to standard rat chow (until food
restriction occurred) and tap water.
2.2.3

Experimental Groups
Rodents were randomly assigned to non-diabetic (n = 12; 6 male, 6 female) or

diabetic (n = 14; 6 male, 8 female) groups. Diabetes induction occurred in the diabetic
group at week 8 of the study. Food restriction commenced at week 14 of the study and
continued until each animal completed all operant conditioning based protocols. Following
the completion of reversal learning (week 16), all animals were sacrificed via
anaesthetization with isoflurane, followed by cardiac exsanguination in accordance with
our animal use protocol.
2.2.4

Experimental Procedures

2.2.4.1

Diabetes Induction

At week 8 of the study, diabetes was induced using a standardized protocol
(Appendix A) via multiple low-dose injections of streptozotocin (STZ; Sigma-Aldrich).
All animals were injected intraperitoneally with 20 mg/kg/day of STZ (dissolved in citrate
buffer; 0.1M, pH = 4.5) for 7 consecutive days. All injections were administered within 10
minutes of final preparation of STZ. T1DM was confirmed with a blood glucose
measurement of ≥ 15 mmol/L taken at approximately 48 hours following the final injection.
2.2.4.2

Insulin Pellet Modulation

Approximately 72 hours following the final injection of STZ and confirmation of
T1DM, all animals in the diabetic group were given a single insulin pellet (1 pellet = 2 IU
insulin/per day; Linshin). Insulin pellets were surgically implanted (Appendix B) by
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trained personnel into the abdomen through a small subcutaneous incision (~ 0.75 cm).
Insulin dosing was modulated in response to blood glucose levels via removal or insertion
of additional pellets. Blood glucose was intended to be maintained within a range of 9 - 15
mmol/L.
2.2.4.3

Food Restriction

In week 14 of the study, all animals were separated into individual cages and placed
on a food restricted diet according to a fixed schedule dictating minimum feeding values
(Appendix C). Animals were closely monitored for abnormalities and weighed daily to
calculate the appropriate amount of food to induce weight loss. All animals were fed at
either ~ 08:00 AM daily, or upon completion of their set-shifting protocol for the day (if
applicable). Diabetic animals had their daily allotment of food split into two boluses given
approximately 12 hours apart in order to limit hypoglycemic episodes. Once each animal
had reached ~ 95% of free-feeding body weight (5% weight loss), operant conditioning
protocols commenced. Animals were maintained at 90 - 95% free-feeding weight for the
duration of the study. Water was provided ad libitum throughout the food restriction period.
2.2.4.4
2.2.4.4.1

Operant Conditioning Protocols
Apparatus

All procedures were conducted in an operant conditioning chamber (Med
Associates) housed within a sound and light attenuating box. The chamber was fitted with
two retractable response levers (on the same wall) with a stimulus light above each. The
levers were separated by a food pellet receptacle in the middle. A house light was located
on the top portion of the opposite wall, serving to illuminate the entire chamber. All aspects
of testing were controlled via MED-PC software (Med Associates). In response to a correct
lever press, a 45 mg sucrose pellet (BioServ) was released into the receptacle from a
dispenser housed outside the chamber.
2.2.4.4.2

Acclimatization and Pre-Training

On each of the 3 days preceding pre-training, each animal was given ten sucrose
pellets in their home cage (in addition to their daily allotment of rat chow) in order to
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familiarize them with the taste and texture. On the day that 95% free-feeding weight was
achieved, rats were placed in the operant chamber for 20 minutes each in order to
acclimatize them. Randomly throughout their time in the chamber, five pellets were
released in order to establish a contingency between the receptacle and a food reward
(sucrose pellet). On the day following acclimatization, each rat commenced a manual
training protocol (pre-training) in order to establish a contingency between the pressing of
the levers and a food reward. To start, the left lever was extended, and when the rat came
into close proximity or interacted with it, the lever was manually retracted and a pellet was
dropped into the receptacle. This process was repeated until the rat learned to press the
lever, at which point it would automatically retract, and a sucrose pellet would be released.
This continued until the rat achieved fifteen presses, at which time the left lever was
retracted and the right lever was deployed. Pre-training was satisfied when fifteen
consecutive left lever presses, fifteen consecutive right lever presses, and thirty alternating
lever presses were achieved within the same session. If unsuccessful after 90 minutes, the
animal was returned to their home cage, and the entire process was repeated the following
day until all sixty presses were achieved within the same session. The house light remained
switched on throughout the entire duration of pre-training.
2.2.4.4.3

Training

On the day following successful completion of pre-training, animals began an
automated training protocol to establish a temporal contingency whereby they learned to
press the lever within a timely (10 s) manner to receive a food reward. Animals were placed
in the operant chamber, this time with the house light switched off. Upon commencement
of the protocol, the house light would illuminate and simultaneously, either the left or right
lever would be randomly extended. The lever would remain extended for 10 s or until the
rat pressed it. If the rat did not press the lever, it was retracted and the house light
automatically switched off. No food reward was given in this instance and it was recorded
as an omission. If the rat did press the lever, it was automatically retracted immediately,
and at the same time, a sucrose pellet was dropped into the receptacle. The house light
remained on for an additional 4 s whilst the rat consumed the pellet. This was counted as a
successful press. Regardless of the outcome, a 10 s inter-trial period with the house light
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remaining off would ensue, after which the entire process would be repeated. This period
of lever deployment and the inter-trial period immediately following constitutes one trial.
Training consisted of ninety successive trials and took approximately 30 minutes to
complete. In order to progress to the next task, rats must have achieved eighty-five or more
successful presses (i.e. five or fewer omissions). If unsuccessful, rats were returned to their
home cage and the entire process was repeated the following day until the criterion was
satisfied.
2.2.4.4.4

Side Bias Determination

Immediately following successful completion of training, a protocol was initiated
to determine the rat’s side bias. The first trial began with the illumination of the house light
and the presentation of both levers. If either of the levers were pressed, they would both be
immediately retracted and a pellet was awarded. The house light would remain on for an
additional 4 s, after which the 10 s inter-trial period would occur (house light off). If neither
of the levers were pressed after 10 s, they would both be immediately retracted with no
pellet awarded and the house light would immediately extinguish. The same 10 s inter-trial
period would occur, after which both levers would present again and the same process
would occur. In the trial directly following a successful press (either lever yielded a reward
in the initial trial), both levers would be presented, however this time, only the lever
opposite the one pressed in the trial prior would trigger a reward. If the rat pressed the same
lever as the one in their initial trial, no pellet was deployed, the house light was turned off,
and the inter-trial period occurred. Trials would continue until the rat successfully pressed
the opposite lever; at which time they would be awarded a pellet. Once two correct presses
had been achieved (i.e. either lever initially, then the opposite lever), the entire process
would reset, and now either lever would again yield a pellet. This protocol ended when the
rat had completed seven correct pairs (i.e. fourteen total correct presses). The side bias was
determined to be the side that initiated the majority of the presses (i.e. responses to the
trials where either lever yielded a reward), or if one lever was pressed twice as many times
(or more) than the other lever, this side would automatically be determined as the rat’s side
bias.
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2.2.4.4.5

Visual Cue Discrimination (VCD)

Once training had successfully been completed and a side bias was ascertained, a
VCD task was initiated on the following day. This task was the first to utilize the cue lights
located above each lever. In this paradigm, rats would only receive a food reward if they
pressed the lever that corresponded to the illuminated stimulus (cue) light. A trial began
with the random illumination of either the left or right cue light. After 3 s of the cue light
being on, the house light was automatically switched on and both levers were presented.
Only the lever positioned directly under the illuminated cue light would produce a sucrose
pellet. If the incorrect lever was pressed (i.e. the lever opposite the illuminated cue light),
both levers were retracted, no pellet was awarded, and the inter-trial period began. If the
correct lever was pressed, both levers were retracted, a pellet would be released, and the
house light would remain on for an additional 4 s, after which the inter-trial period
occurred. If neither lever was pressed after 10 s, no pellet was awarded, both levers were
retracted, and the inter-trial period began. This was scored as an omission. All rats
underwent 100 consecutive trials in one session. The performance criterion was set as ten
consecutive correct trials (omissions were not counted against this). If rats did not achieve
criterion on the first session, they were returned to their home cage and retested the
following day until criterion was reached. Both the total number of trials to criterion, and
the total number of errors to criterion were measured. Errors to criterion were the total
number of errors that were incurred until criterion was achieved. Errors that occurred after
criterion had been achieved were not scored against this.
2.2.4.4.6

Set-Shifting: Response Discrimination (RD)

On the day following successful completion of VCD, rats were provided a brief
visual cue retrieval (VCR) test consisting of twenty VCD trials (identical to the previous
day) to ensure that they retained the visual cue paradigm. In order to proceed to the RD
task, rats must have successfully completed at least sixteen of the twenty VCR trials (≥
80%; Appendix D). If rats did not achieve this, they were then given 100 more VCD trials
and returned to their home cage to attempt VCR the following day. Immediately following
successful completion of the recall test (VCR), the paradigm shifted to a RD task in which
the visual cue became irrelevant. In the RD trials, a random cue light preceded the
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presentation of both levers and the illumination of the house light by 3 s (same as VCD).
However, now only the lever opposite the rat’s pre-determined side bias produced a reward,
regardless of the cue light. Rats had to un-learn the old VCD contingency (i.e. follow the
light) and adopt the new RD one (i.e. only press lever opposite side bias). Correct trials,
incorrect trials, and omissions all invoked the same respective responses outlined above in
prior tasks. Performance criterion was again set as ten consecutive trials with omissions
having no impact. All rats underwent 120 trials per session. If rats did not achieve criterion
on the first session, they were returned to their home cage and retested the following day
until criterion was reached. Trials and errors to criterion, as well as total number and type
of errors were measured.
One key difference in the RD task was that trials were delivered in blocks of sixteen
featuring eight congruent and eight non-congruent trials randomly dispersed throughout.
A congruent trial was one in which the cue light corresponded to the correct lever. In these
trials, the rat would be rewarded regardless of which paradigm they were adhering to, since
the old VCD strategy was still correct in these trials. An incongruent trial was one in which
the cue light did not correspond to the correct lever, meaning that the rat must follow the
new RD strategy in order to receive a sucrose pellet (i.e. only the lever opposite the cue
light yielded a reward). As such, incongruent trails indicated which strategy rats were
adhering to (VCD or RD).
2.2.4.4.7

Reversal Learning (RL)

Once criterion had been reached on the RD task, rats were next assessed on their
ability to adopt the opposite RD strategy the following day. The protocol used was identical
to the RD task, except that this time only the lever corresponding to the rat’s side bias
yielded a reward (i.e. the opposite lever as in the previous day’s RD task). All rats received
120 trials and were assessed on trials and errors to criterion, as well as number and type of
errors. Note that each animal only underwent a single testing session (120 trials) of RL.
This is different than the VCD and RD tasks, in which animals were retested on subsequent
days if they did not achieve criterion within the first testing session.
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2.2.4.4.8

Error Analysis

In the RD task, errors were categorized as either perseverative, regressive, or neverreinforced. Both perseverative and regressive errors were scored when the incorrect lever
was pressed on incongruent trials. Perseverative errors typically occurred earlier in the RD
task and were an indication that the rat was adhering to the old VCD strategy. Regressive
errors were typically scored later in the task and represented the rat’s inability to maintain
the new RD strategy. Perseverative and regressive errors were scored in the same way in
the RL task. Never-reinforced errors were counted only in the RD task and were scored
when the incorrect lever was pressed on congruent trials. These errors indicated that the rat
was not adhering to either the VCD nor the RD strategy and was perhaps attempting to
learn by filtering out incorrect responses.
2.2.5

Experimental Measures

2.2.5.1

Body Weight and Blood Glucose

Body weight and non-fasted blood glucose were recorded on a weekly basis at a
consistent time of day (09:00 AM ± 1 hr) throughout the entire duration of the study. Body
weight was measured to the nearest gram using a standard digital scale and weigh basket.
In order to analyze blood glucose, a small blood sample (~ 50 µL) was obtained from the
saphenous vein of the hind leg via needle prick. Pressure was applied with gauze in order
ensure hemostasis was achieved following blood collection. Blood glucose values were
obtained using a Freestyle Lite Blood Glucose Monitoring System (Abbott Diabetes Care)
and reported in millimoles per litre (mmol/L).
2.2.5.2

Visual Cue Discrimination

All data were captured and analyzed using proprietary MED-PC software (Med
Associates) and custom designed protocols see (Appendix E). Total number of trials to
criterion, as well as total number of errors to criterion were analyzed. Criterion was set at
ten consecutive correct responses for the VCD task. It should be noted that for all tasks, a
lower number of trials to criterion is indicative of faster learning (superior performance).
Similarly, a lower number of errors to criterion also indicates higher relative performance
(fewer errors to learn a new paradigm).
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2.2.5.3

Set-Shifting: Response Discrimination

Total number of trials to criterion, total number of errors to criterion, as well as
number of perseverative, regressive, and never-reinforced errors were computed. Criterion
was set at ten consecutive responses, and any omission that occurred in a string of
consecutive trials towards criterion did not reset progress. Errors were analyzed in blocks
of sixteen, with each block containing eight congruent and eight non-congruent trials.
Perseverative errors were scored as such when rats selected the incorrect lever on six or
more of the eight incongruent trials in a block. Conversely, regressive errors were scored
as such when rats selected the incorrect lever on five or fewer of the eight incongruent trials
in a block. Never-reinforced errors were scored when rats responded incorrectly on any
congruent trial, regardless of the block.
2.2.5.4

Reversal Learning

Total number of trials to criterion, total number of errors to criterion, as well as
number of perseverative and regressive errors were computed. Similarly to the RD task,
criterion was set at ten consecutive responses, and omissions did not affect criterion
attainment. Perseverative and regressive errors were analyzed and scored as outlined above
(section 2.2.5.3). Since both RD paradigms had now occurred (i.e. both the ‘non-biased’
lever and the ‘biased’ lever have yielded a reward) as of RL, never-reinforced errors were
no longer applicable, as they were previously reinforced in the RD task. Therefore, they
were not analyzed in this task. Animals in the RL task did not undergo more than one
testing session (120 trials), and as a result, not all animals achieved criterion.
2.2.6

Data Analysis
Weekly body weight and blood glucose values were analyzed using a two-way

repeated measures analysis of variance (ANOVA) with time and diabetic status (nondiabetic vs. diabetic) as factors using GraphPad Prism 8 (GraphPad Software
Incorporated). Post-hoc analysis was performed using a Sidak’s multiple comparisons test.
Trials to criterion and errors to criterion for all three tasks (VCD, RD, and RL), were
analyzed using unpaired t-tests. Error types for the RD task (perseverative, regressive, and
never-reinforced) were analyzed using a two-way ANOVA with diabetic status and error
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type as factors. Post-hoc analysis was performed using Tukey’s multiple comparisons test.
Error types for the RL task (perseverative and regressive) were analyzed using a two-way
ANOVA. Post-hoc analysis was performed using Sidak’s multiple comparisons test.
Statistical significance was set at a value of α = 0.05 for all analyses.

2.3 Results
2.3.1

Animal Characteristics
Body weight and blood glucose were both independently analyzed to determine the

impact of diabetic status (non-diabetic vs. diabetic) and time (week of study). Twenty-six
rats (non-diabetic = 12, diabetic = 14) were included in final analysis for all measures. The
original cohort included sixteen diabetic rats, however two males died throughout the
course of the study and data from these animals were removed from all analyses.
For body weight (Fig. 1a), there was a significant interaction between diabetic
status and time (P < 0.0001). The impact of diabetic status on body weight was not
statistically significant (P = 0.1800). Post-hoc analysis revealed no significant differences
between non-diabetic and diabetic groups at any time point. Diabetic animals lost ~ 17%
body weight following diabetes induction (week 8 vs. week 9; P = 0.0003). This is a typical
result of the diabetes induction protocol that has been observed in past works by our
laboratory. Diabetic animals recovered their weight by week 13 (week 8 vs. week 13; P >
0.9999). A reduction in body weight (non-significant; week 14 vs. week 15 non-diabetic;
P = 0.0796; week 14 vs. 15 diabetic; P > 0.9999) can also be observed at week 15 as a
result of the food restriction protocol.
For blood glucose (Fig. 1b), there was also a significant interaction between
diabetic status and time (P < 0.0001). The impact of diabetic status was significant on blood
glucose levels (P < 0.0001). Post-hoc analysis revealed statistically significant differences
in blood glucose levels at weeks 9, and 11 - 15 (P ≤ 0.0003 for all). There was no blood
glucose data obtained during week 8, as diabetic animals were biohazardous for a 10 day
period during and following diabetes induction. As a result, biological samples could not
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safely be collected. All blood glucose values for week 15 were obtained immediately
following each animals operant conditioning task for the day. Values were elevated at this
time due to the consumption of up to 140 sucrose pellets (6.3 g total) throughout the
duration of testing.
2.3.2

Visual Cue Discrimination
There were no significant differences in the number of trials to criterion (P =

0.1294), nor the number of errors to criterion (P = 0.1244) between the non-diabetic and
diabetic groups in the VCD task. Data are visualized in Fig. 2.
2.3.3

Set-Shifting: Response Discrimination
No significant differences were observed in the number of trials to criterion (P =

0.2991), nor number of errors to criterion (P = 0.3733). There was no significant interaction
observed between diabetic status and error type (P = 0.9350). Post-hoc analysis confirmed
that there were no differences in the number of perseverative (P > 0.9999), regressive (P =
0.9852), or never-reinforced (P = 0.9976) errors made between non-diabetic and diabetic
groups. There were significantly more perseverative errors made compared to neverreinforced errors (P < 0.0001), and significantly more regressive errors made compared to
never-reinforced errors (P < 0.0001). There was no difference between the number of
perseverative errors and regressive errors made (P = 0.1541). All RD data are presented in
Fig. 3.
2.3.4

Reversal Learning
Neither number of trials to criterion (P = 0.0601), nor errors to criterion (P =

0.2004) were different between non-diabatic and diabetic groups. Note that not all animals
successfully reached criterion on the RL task, therefore final analysis only included n = 9
non-diabetic and n = 13 diabetic animals for trials to criterion and errors to criterion. Since
criterion attainment did not affect either the total number of errors committed, nor the type
of errors made, final analysis for RL error type included data from all animals. No
significant interaction was found between diabetic status and error type (P = 0.7669). Posthoc analysis confirmed that there were no differences in the number of perseverative (P =
0.6768), or regressive errors (P = 0.9164) committed between groups. Significantly more
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perseverative errors were committed compared to regressive errors within both groups
(non-diabetic perseverative versus regressive P = 0.0018; diabetic perseverative versus
regressive P = 0.0026). All RL data are visualized in Fig. 4.
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Figure 1: (a) Mean body weight (g). Diabetes induction and food restriction occurred at
week 8 and 14, respectively. Diabetic animals lost ~ 17% body weight following diabetes
induction. This was recovered by week 13 (week 8 vs. week 13; P > 0.9999). Both groups
slightly declined in body weight from week 14 to 15 as a result of food restriction. There
was no significant impact of diabetic status on overall body weight. Post-hoc analysis
revealed no significant differences between groups at any time point. Figure 1 (a) and (b)
data are presented as mean ± SEM.
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(b) Mean non-fasted blood glucose (mmol/L). Diabetes induction and food restriction
occurred at week 8 and 14, respectively. No blood glucose data was obtained for week 8
as animals were biohazardous and biological samples could not safely be collected. Note
that there are no error bars displayed for the non-diabetic group as they are too small to
be visualized. Analysis revealed a significant impact of diabetic status on blood glucose.
Post-hoc analysis revealed significant differences between groups at weeks 9, and 11 15. * Denotes P ≤ 0.0003.
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Figure 2: (a) Visual cue discrimination (VCD) trials to criterion. No significant
differences were observed between groups. Figures 2, 3, and 4 data are presented as
mean ± SD with each dot representing an individual data point.
(b) VCD errors to criterion. No significant differences were observed between groups.
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Figure 3: (a) Response discrimination (RD) trials to criterion. No significant differences
were observed between groups.
(b) RD errors to criterion. No significant differences were observed between groups.

43

(c) RD errors sorted by type. No significant differences were found between groups.
Significantly more perseverative and regressive errors were committed compared to neverreinforced errors (**** denotes P < 0.0001 for both comparisons).
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Figure 4: (a) Reversal learning (RL) trials to criterion. Note that not all animals reached
criterion in this task, therefore final analysis for RL trials to criterion and errors to
criterion only included n = 9 non-diabetic and n = 13 diabetic animals. No significant
differences were observed between groups.
(b) RL errors to criterion. No significant differences were observed between groups.
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(c) RL errors sorted by type. Note that never-reinforced errors were not applicable in the
RL task. No significant differences were observed between groups. Significantly more
perseverative errors were committed compared to regressive errors by both groups (**
denotes P < 0.01).
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2.4 Discussion
In the present study, we examined the impact of T1DM on EF using a series of
operant conditioning based tasks. Contrary to our hypothesis, the results presented suggest
that T1DM rats do not show decrements on tests of EF nor set-shifting compared to nondiabetic rats. Although this finding may not directly align with similar prior research in
humans that demonstrated subtle impairments in EF in patients with T1DM
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, to our

knowledge, the present study was the first to specifically analyze the executive function of
the T1DM rat.
Statistical analysis revealed that diabetic status (i.e. non-diabetic vs. diabetic) had
no significant impact on body weight. Although diabetic animals lost on average ~ 17%
body weight following diabetes induction (week 8 vs. week 9; P = 0.0003), they eventually
recovered their body weight to pre-diabetic levels by week 13 (mean week 8 = 384.43 g;
mean week 13 = 384.21 g; P > 0.9999). As anticipated, both groups declined as a result of
food restriction (non-significant; week 14 vs. week 15 non-diabetic; P = 0.0796; week 14
vs. 15 diabetic; P > 0.9999). There was a significant impact of diabetic status on blood
glucose levels (P < 0.0001). Post-hoc analysis revealed significant differences between
groups at weeks 9, and 11 - 15 (P ≤ 0.0003 for all). Due to the nature of the insulin therapy
used, blood glucose levels are lowest immediately following insulin pellet implantation
(week 9), which may explain why no differences were observed between groups at week
10.
In the visual cue discrimination task, no differences were found in the number of
trials, nor errors to criterion between non-diabetic and diabetic rats. Statistical analysis of
both trials, and errors to criterion, as well as total error number and type in the response
discrimination , and reversal learning tasks also revealed no significant differences between
the two groups. Taken together, these data suggest that an insulin-treated rodent model of
T1DM does not show any decrement in cognitive function, or more specifically executive
function.
Several reasons may explain the apparent preservation of EF. Perhaps most
significantly, our diabetic group utilized an insulin-treated model of T1DM. Although
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rodents in the T1DM group had significantly higher blood glucose than those in the nondiabetic group (Fig. 1b), they were maintained within a tighter range compared to other
works that did not attempt to regulate glycemia 23-27, 31, 43, 44. It is plausible that these levels
of extreme hyperglycemia were at least partially responsible for the cognitive deficits
observed in these works. Further evidence to support this comes from works that have
demonstrated the efficacy of insulin treatment at ameliorating cognitive deficits in T1DM
rodents when specifically compared to non-insulin treated T1DM groups 18, 19, 32. Similarly,
data from human work has shown that those with higher HbA1c concentrations (indicative
of periods of sustained hyperglycemia) showed inferior performance on measures of
cognition 9. It is purported that poor long-term metabolic control (higher HbA1c) increases
diabetic comorbidities such as microvascular complications

16

which have been

independently correlated to impaired cognition 8.
There is significant research demonstrating the deleterious impact of T1DM on
systemic vasculature, much of which has focused on the eyes, kidneys, heart, and
extremities

45-48.

Furthermore, previous work from our laboratory has demonstrated

reductions in vascular function using the same T1DM model as the present study

49,

however cerebral vasculature was not examined. Other studies have specifically explored
cerebral vascular function in T1DM, generally reporting attenuated function. More
specifically, cerebral blood flow has been shown to be markedly reduced in STZ-induced
T1DM rodent models

50, 51.

However, these reductions appear to be region specific and

were shown to disproportionately affect the hippocampus, while sparing the
‘nontelencephalic’ regions (i.e. the cerebrum which includes the mPFC) 50. This could in
part explain why many past works that emphasized mainly tests of hippocampal function
reported performance decrements

19, 23-32,

while the present work, which mainly assesses

mPFC function does not. Future projects that assess executive function should specifically
examine cerebral blood flow to different regions the brain, namely the cerebral lobes and
prefrontal cortex.
The age at diabetes onset may have been another contributing factor in our results.
Diabetes was induced in week 8 of the study, which was approximately week 16 of the
rodent’s lifespan. At this age, and body weight (Fig. 1a) Sprague Dawley rats are sexually
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mature and are in adulthood

52.

Research outlined above has shown that those with an

earlier age at disease onset, defined as younger than 7 years of age in humans, showed
more significant cognitive impairments than those with a later age at onset 12, 13. Although
developmental periods do not align with humans, it is possible that rats were already past
the more vulnerable periods of brain development that were theorized to exacerbate
cognitive impairments in early onset humans

53.

In accordance with this, several other

animal works that reported cognitive dysfunction induced T1DM at a younger age
(approximately week 8 of the rodents’ lifespan) 23, 26, 54, 55. However, data from Kamal et
al.
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showed that rats induced at both 3 and 22 months of age showed inferior MWM

performance compared to age matched controls, indicating that age at diabetes onset may
not necessarily play a significant role.
Another important consideration may be the duration of diabetes. In the present
study, rats were diabetic for approximately 8 weeks by completion of the final RL task. It
is possible that this disease course was not long enough to cause any detectable functional
changes. In what is perhaps the most widely cited evidence of cognitive dysfunction in
T1DM, Brands et al. 8 reported that there was no consistent relationship between disease
duration and cognition. However, they only included studies in which T1DM groups had
been diagnosed with diabetes for a minimum of 18 years. Perhaps it is possible that had
they included studies with shorter disease durations, they may have seen a correlation.
However, past animal studies have shown that performance decrements were evident in as
few as 3 - 4 weeks of diabetes 19, 55. Interestingly, Rajashree et al. 56 reported that cognitive
decrements worsened with disease course, showing that increased cognitive deficits were
observed in rats that had been diabetic for 20 days compared to those who were only
diabetic for 10 days. Although it is possible that our disease course was not adequate to
induce observable cognitive changes, it would appear based on these works that changes
are evident even after a few weeks of T1DM. It is perhaps more likely based on the
evidence outlined above that other factors such as the role of insulin treatment may explain
the lack of EF differences between non-diabetic and diabetic groups observed in the present
study.
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One significant finding in the present study was that there were significantly more
perseverative and regressive errors made compared to never-reinforced errors by both
groups in the RD task (P < 0.0001 for both comparisons). Similarly, there were more
perseverative errors committed than regressive errors in the RL task by both groups (nondiabetic P = 0.0018; diabetic P = 0.0026). This aligns with the work of others using the
same operant conditioning based tasks 40-42. Floresco et al. 40 hypothesized that due to the
fixed spatial orientation of the chamber, rats may have fewer strategies at their disposal
compared to other assessments of behavioral flexibility such as the radial arm maze

57.

Given that perseverative errors are indicative of a failure to adopt a new strategy, it is
plausible that rats have a greater propensity to adhere to the former cue rather than seeking
out the novel, correct cue 40.

2.5 Limitations and Future Directions
To our knowledge, this study is the first to assess the EF abilities of an insulintreated T1DM rodent model. Furthermore, we included both male and female rodents to
incorporate a representative sample of the T1DM population. In summary, we have
demonstrated that non-diabetic and insulin-treated T1DM rodents show no differences in
their executive function, nor set-shifting abilities. Given the exploratory nature and novelty
of this project, it is important to highlight certain limitations. Firstly, we were limited by
our sample size due to constraints in the number of rodents that could be procured and
properly managed within the project timeframe. Furthermore, we recognize that the rodents
in the non-diabetic group were not subjected to the same experimental stressors as those in
the diabetic group (i.e. injections, anesthetization, and surgery in non-diabetic animals may
have impacted our results). Another limitation may have stemmed from potential visual
impairments amongst the diabetic rodents. As outlined in the literature review,
retinopathies are a common comorbidity of T1DM and may adversely affect vision.
Although we did not specifically test for visual deficits, all rodents were carefully
monitored by both study investigators and veterinary staff for any abnormalities, especially
throughout the testing period. Given that neither party noted any visual abnormalities in
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the diabetic rodents in the present study, we feel confident that visual disturbances did not
impact our results.
Future work should aim to employ a larger sample size, ensuring each group
receives identical treatment by subjecting non-diabetic rodents to saline injections and
sham surgeries. Future studies that adjust variables such as the age at diabetes induction,
disease duration, and treatment interventions (e.g. insulin) in order to gauge their impact
on executive function are also warranted. Post-mortem analysis of the brain, cerebral blood
flow, and other measures of vascular health may provide valuable insight into the
mechanisms of EF in T1DM rats. More specifically, structural and biochemical analysis of
the underlying brain regions that have been shown to govern EF such as the mPFC may be
warranted.

2.6 Conclusion
In conclusion, this study has demonstrated that there are no significant differences
in the executive function nor set-shifting ability of non-diabetic and T1DM rats. We
hypothesized that insulin-treated T1DM rats would show impairments in EF, specifically
manifested as an increased number of trials and errors to criterion in the response
discrimination task. However, data from the present study demonstrates that there were no
significant differences between groups in any of the operant conditioning measures
obtained. It is possible that the age at diabetes induction, diabetes duration, and treatment
interventions (insulin) prevented us from observing any cognitive decrements in the T1DM
group. Future work may look to alter these variables, while taking into consideration some
of the limitations of the present study. The adoption of additional experimental measures
such as biochemical and/or histological analysis of the mPFC may provide valuable insight
into the physiology of the T1DM rodent brain.
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Appendices
Appendix A: Multiple Low-Dose Streptozotocin Injections
Purpose: To induce Type 1 Diabetes Mellitus in rats
Materials: Gloves, Lab Coat, Streptozotocin (STZ), 5X Stock Citric Acid/Citrate Buffer,
Anhydrous Citric Acid, Sodium Citrate Dihydrate, MilliQ Deionized Water, 13M HCl,
Falcon Tubes, Sterile Filter
Equipment: Biological Safety Cabinet Weigh Scale pH Meter
Procedure:
Preparing 5X Citric Acid/Citrate Buffer
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add:
a. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate
b. 23.8g Sodium Citrate Dihydrate (Sigma), Mix into…
c. 175mL of MilliQ water the pH should be at 4.6, Add HCl or NaOH to
adjust (do not over-shoot pH)
2. Once the proper pH is attained, add MilliQ water until you are close to the 200 ml
mark (pH will move slightly). If satisfied with the pH, adjust volume in a 250 ml
graduated cylinder and filter in a 0.2µm filter.
3. Store at room temperature. This is your 5X stock solution.
Mixing and dosing STZ for injection (Note: animals should be weighed prior to dosing
STZ to ensure accurate amounts)
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1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL
of distilled water filtered through a 0.2µm syringe filter. Check the pH. This gives
you a working concentration of 153 mM.
2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of
concentrated HCl to the buffer, checking pH in between until desired pH is
reached.
3. Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm
syringe filter as before). If pH is below 4.5, restart.
4. Weigh out an appropriate amount of STZ for the number of animals (see
calculations below) that will be injected in a 15-minute time frame. Ex. Rats will
be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g (avg. weight
of rats to be injected), you will require a minimum of 40mg. 20mg/kg X 0.2kg =
4mg per animal.
5. The amount of STZ weighed out should be more than the minimum as some
solution will be lost in filtering. (4mg (per animal) X 12 rats = 48mg total
(0.048g).
6. Dissolve the STZ into buffer (keeping in mind a comfortable injection volume).
Shake to dissolve powder (approx. 1 min). Sterile filter using a 0.2µm syringe
filter. Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution 4mg ÷ 16mg/mL
solution = 0.25mL. STZ is time dependent and must be used within 15 minutes.
7. Injecting and Follow-Up of the Animals 1. Promptly inject each rat with the
solution (intraperitoneal) at a dosage rate of 20mg/mL (in this example, 0.25mL).
Do not use anymore STZ solution more than 15 minutes after it has been
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dissolved in the sodium citrate buffer. 2. Dispose of any container having come
into contact with the STZ (in either powder or dissolved form) into a
biohazardous waste receptacle. Dispose of needles into a sharp’s container. 3.
Return injected rats to their cage. Record the date of STZ injection and add a
biohazard label to the cage (leave biohazard label on cage for at least 3 days
following the last injection). 4. Repeat this procedure the following day. 5. Check
blood glucose daily. Diabetes is achieved with two non-fasting blood glucose
readings of > 15 mmol/L. Diabetes should be achieved after 5-8 injections.
References:
Low dose STZ induction protocol. Animal Models of Diabetic Complications
Consortium AMDCC Protocols. 2003
O’Brien BA, Harmon B V, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for
the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178:
176–181, 1996.
Melling CWJ, Grisé KN, Hasilo CP, Fier B, Milne KJ, Karmazyn M, Noble EG. A model
of poorly controlled type 1 diabetes mellitus and its treatment with aerobic exercise
training. Diabetes Metab 39: 226–235, 2013.
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Appendix B: Insulin Pellet Implantation
Pellet implantation (for a rat):
1. Anesthetize the animal using the isoflurane machine by placing it in the induction
chamber. Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open the
stopcock valve so gas reaches the chamber. Keep in chamber until the animal is
unconscious.
2. Remove the animal and place its nose in the nose cone, reduce the isoflurane to
3% to maintain the plane of anesthesia.
3. Shave the area where the pellet is to be implanted.
4. Using gauze (or a swab), apply 10% povidone-iodine solution to the skin,
followed by 70% ethanol, to disinfect the site of insertion.
5. Hold the skin with forceps and make a subcutaneous incision.
6. Cleanse a 12g trocar with 10% povidone-iodine solution and insert it through the
puncture site at least 2 cm horizontally from the incision site.
7. Using forceps, briefly immerse the pellet in 10% povidone-iodine solution, rinse
with saline and insert into the subcutaneous region.
8. Use 1 pellet for up to the first 350g of body weight.
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 %
povidone-iodine solution over the opening.
10. Close the incision by suturing.
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
12. Record on the cage card that insulin pellets have been implanted.
Pellet removal:
1. Anesthetize the animal as described above for implantation.
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by
applying 10% povidone-iodine solution followed by 70% ethanol.
3. Using a scalpel (or scissors), make an incision through the skin superficial to the
location of the pellets.
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4. Using forceps, remove the pellet. Some connective tissue may need to be cut
away using scissors. Discard the pellet.
5. Close the incision by suturing.
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
7. Record on the cage card that the pellets have been removed.
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Appendix C: Food Restriction Schedule

Note: all values provided are minimums. In certain instances, diabetic animals were
allotted slightly more than the minimum allowance in order to stabilize weight and blood
glucose levels.
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Appendix D: Visual Cue Retrieval Data

Note: All animals scored ≥ 80% (i.e. at least sixteen correct trials) in order to proceed to
the RD task.
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Appendix E: MED-PC to Excel Workbook Instructions
MED-PC to Excel Conversion
1. Open MPC2XL.EXE (MED-PC to Excel)
2. Under “Row Transfer” in the “Transfer Data” tab, press “Select”
3. Open “$Visual cue discrimination.MRP” for visual cue discrimination files, open
“$Shift Response Discrimination.MRP” for response discrimination files.
4. Make sure both “Column Labels” and “Data” are select under the “Transfer” box
5. Select “Vertical (Column)” under the “Orientation” box
6. Open Excel workbook and ensure that the A1 cell on the first tab (Input) is selected;
this applies to both workbooks. Transferring data into any other cell can cause
irreversible malfunction of the workbooks.
7. Return to MED-PC to Excel, press “Transfer”, select raw data file
Visual Cue Workbook
Once data is transferred into Visual Cue Workbook.xlsm, key measures will appear in cells
E3-5: Trials to Criterion, Errors to Criterion, Errors after Criterion. Criterion is set to 8
consecutive correct response. Omissions do not reset a series of correct responses. Rows
27-426 show raw data with annotations: Trial number, whether criteria has been met,
running total counts of errors, and running counts of consecutive correct responses
(performance).
Response Discrimination Workbook
The Excel workbook Response Discrimination Workbook.xlsm requires the use of VBA
macros. To enable the use of VBA macros in excel, users must first enable the developer
tab (see “Show the Developer tab” in Microsoft Office Support documentation) and
enable macros (see “Enable or disable macros in Office files” in Microsoft Office
Support documentation).
Once Data is transferred into Response Discrimination Workbook.xlsm, go to the
‘Developer’ tab and select ‘Macros’. Run Compiled_Left2 (shortcut key: Ctrl + Shift + E)
or Compiled_Right2 (shortcut key: Ctrl + Shift + R) depending on whether the left or right
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lever was selected to be rewarding, respectively. If uncertain which lever was selected to
be rewarding in a given experiment, the raw data file can be inspected using a text editor
such as Notepad or Word (Microsoft) and the experiment protocol can be found next to
‘MSN:’ as either $Shift Response Discrimination LEFT or $Shift Response Discrimination
RIGHT corresponding to left or right rewarding levers, respectively. Once the
Compiled_Left/Right2 macro is run, Excel should end on the Summary tab with error
profile data.
To reset the workbook, run the Clear All macro (shortcut key: Ctrl + Shift + C).
To produce a list of errors for each incongruent trial, as required for logistic regression
modelling, run Compiled_Left (shortcut key: Ctrl + E) or Compiled_Right (shortcut key:
Ctrl + R) on transferred data. Return to the Input tab and copy the data under Column D
which will indicate ‘1’ for incorrect lever presses or ‘0’ for correct lever presses or
omissions for all incongruent trials in order from the top of the column to the bottom.
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Appendix F: Animal Use Protocol Approval
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